HK1258688A1 - 预测药物敏感性、抗性和疾病进展的组合物和方法 - Google Patents

预测药物敏感性、抗性和疾病进展的组合物和方法 Download PDF

Info

Publication number
HK1258688A1
HK1258688A1 HK19101066.6A HK19101066A HK1258688A1 HK 1258688 A1 HK1258688 A1 HK 1258688A1 HK 19101066 A HK19101066 A HK 19101066A HK 1258688 A1 HK1258688 A1 HK 1258688A1
Authority
HK
Hong Kong
Prior art keywords
cancer
cells
molecule
sample
disease
Prior art date
Application number
HK19101066.6A
Other languages
English (en)
Chinese (zh)
Inventor
D‧P‧克拉克
A‧沙姚伟茨
C‧卡布拉迪拉
A‧沙姚偉茨
Original Assignee
生物标志物策略公司
生物標誌物策略公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 生物标志物策略公司, 生物標誌物策略公司 filed Critical 生物标志物策略公司
Publication of HK1258688A1 publication Critical patent/HK1258688A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK19101066.6A 2010-04-19 2019-01-22 预测药物敏感性、抗性和疾病进展的组合物和方法 HK1258688A1 (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US32571710P 2010-04-19 2010-04-19
US61/325,717 2010-04-19
US35649510P 2010-06-18 2010-06-18
US61/356,495 2010-06-18
US42117810P 2010-12-08 2010-12-08
US61/421,178 2010-12-08
US201161443146P 2011-02-15 2011-02-15
US61/443,146 2011-02-15

Publications (1)

Publication Number Publication Date
HK1258688A1 true HK1258688A1 (zh) 2019-11-15

Family

ID=44834747

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19101066.6A HK1258688A1 (zh) 2010-04-19 2019-01-22 预测药物敏感性、抗性和疾病进展的组合物和方法

Country Status (12)

Country Link
US (1) US9766249B2 (cg-RX-API-DMAC7.html)
EP (1) EP2561368B1 (cg-RX-API-DMAC7.html)
JP (2) JP6158078B2 (cg-RX-API-DMAC7.html)
KR (1) KR101977875B1 (cg-RX-API-DMAC7.html)
CN (2) CN102947706B (cg-RX-API-DMAC7.html)
AU (1) AU2011242990B2 (cg-RX-API-DMAC7.html)
CA (1) CA2795362C (cg-RX-API-DMAC7.html)
ES (1) ES2650674T3 (cg-RX-API-DMAC7.html)
HK (1) HK1258688A1 (cg-RX-API-DMAC7.html)
PL (1) PL2561368T4 (cg-RX-API-DMAC7.html)
SG (1) SG184507A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011133477A2 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102089444A (zh) 2008-05-14 2011-06-08 德玛泰克国际公司 利用核酸分析方法来诊断黑素瘤和太阳能雀斑
CA2767616A1 (en) 2009-07-09 2011-01-13 The Scripps Research Institute Gene expression profiles associated with chronic allograft nephropathy
WO2014145705A2 (en) 2013-03-15 2014-09-18 Battelle Memorial Institute Progression analytics system
CN104152397A (zh) * 2013-05-13 2014-11-19 复旦大学 一种致敏动物的脾细胞模型及其在药物筛选中的用途
GB201314485D0 (en) * 2013-08-13 2013-09-25 Electrophoretics Ltd Materials and methods relating to pancreatic cancer
WO2015048802A2 (en) * 2013-09-30 2015-04-02 Daiichi Sankyo Co., Ltd. Protein biomarker and uses thereof
WO2019161126A1 (en) 2018-02-14 2019-08-22 Dermtech, Inc. Novel gene classifiers and uses thereof in non-melanoma skin cancers
WO2022187196A1 (en) * 2021-03-02 2022-09-09 Dermtech, Inc. Predicting therapeutic response
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
US11104951B2 (en) 2014-05-22 2021-08-31 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
CN104745700A (zh) * 2015-03-27 2015-07-01 南京医科大学 一种食管癌相关甲基化生物标志物及应用
HRP20191019T1 (hr) * 2015-07-07 2019-09-06 F. Hoffmann - La Roche Ag Kombinacijska terapija konjugatom protutijela i lijeka anti-her2 i inhibitorom bcl-2
CN109072309B (zh) * 2016-02-02 2023-05-16 夸登特健康公司 癌症进化检测和诊断
CN105524973A (zh) * 2016-03-15 2016-04-27 南京华奥生物医药技术有限公司 利用自体肿瘤与正常配对原代细胞筛选肿瘤药物的方法
CN107091930B (zh) * 2017-03-07 2020-09-15 杭州百凌生物科技有限公司 快速预测和提高非小细胞肺癌细胞对表皮细胞生长因子受体抑制剂敏感性的方法
CN107271672B (zh) * 2017-06-21 2019-01-01 首都医科大学附属北京友谊医院 外泌体p-ERK在制备结直肠癌诊断产品中的应用
KR102094802B1 (ko) * 2017-10-24 2020-03-31 고려대학교 산학협력단 소변 대사체 분석을 이용한 베체트병의 진단방법
CN111417730A (zh) * 2017-11-20 2020-07-14 托雷莫治疗股份公司 诊断方法
TWI683905B (zh) * 2017-11-21 2020-02-01 長庚醫療財團法人高雄長庚紀念醫院 用於檢測川崎氏病的方法及套組以及用於治療川崎氏病的方法
JP2022524641A (ja) 2019-03-26 2022-05-09 ダームテック，インク． 皮膚癌における新規な遺伝子分類子とその使用
KR102199141B1 (ko) 2019-05-03 2021-01-06 사회복지법인 삼성생명공익재단 대장암 진단 마커 및 대장암 진단에 필요한 정보를 제공하는 방법
JP2023537260A (ja) * 2020-07-24 2023-08-31 ジェネンテック， インコーポレイテッド バイオマーカーを使用する骨髄穿刺液の血液希釈の決定
CN115267165A (zh) * 2022-08-15 2022-11-01 海仕兰(上海)生物科技有限公司 一种悬浮芯片系统及其应用以及基于悬浮芯片系统对肿瘤伴随诊断因子检测方法
KR20240037082A (ko) * 2022-09-14 2024-03-21 아주대학교산학협력단 항암제 내성 측정용 바이오 마커 및 이를 이용한 항암제 내성 예측 정보 제공 방법
CN118130793B (zh) * 2024-02-26 2025-07-29 赣南医科大学 视网膜母细胞瘤的生物标志物cdk12及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
WO2006026710A2 (en) * 2004-08-31 2006-03-09 The Johns Hopkins University Rapid prognostic assay for malignancies treated with epidermal growth factor receptor
KR101637140B1 (ko) 2005-05-09 2016-07-06 테라노스, 인코포레이티드 현장진료 유체 시스템 및 그 용도
WO2006125143A2 (en) * 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
EP1904657B1 (en) * 2005-06-08 2011-05-25 Hitachi Chemical Research Center, Inc. METHOD FOR PREDICTING IMMUNE RESPONSE TO NEOPLASTIC DISEASE BASED ON mRNA EXPRESSION PROFILE IN NEOPLASTIC CELLS AND STIMULATED LEUKOCYTES
ATE543914T1 (de) * 2005-09-01 2012-02-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegen vegfr2 modulator.
WO2007143183A2 (en) * 2006-06-04 2007-12-13 Soner Altiok Methods for developing and assessing therapeutic agents
EP2899541A1 (en) * 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
JP2010536371A (ja) * 2007-08-21 2010-12-02 ノダリティ，インコーポレイテッド 診断方法、予後および治療方法
ES2535631T3 (es) 2007-10-24 2015-05-13 Biomarker Strategies, Llc Métodos y dispositivos mejorados para análisis celular
WO2009073513A1 (en) * 2007-11-30 2009-06-11 Schering Corporation Braf biomarkers

Also Published As

Publication number Publication date
CA2795362C (en) 2018-03-20
CA2795362A1 (en) 2012-10-02
JP6580546B2 (ja) 2019-09-25
PL2561368T3 (pl) 2018-03-30
CN102947706B (zh) 2018-04-13
SG184507A1 (en) 2012-11-29
CN108535465A (zh) 2018-09-14
WO2011133477A2 (en) 2011-10-27
US20120094853A1 (en) 2012-04-19
ES2650674T3 (es) 2018-01-19
AU2011242990B2 (en) 2015-02-12
JP2013525786A (ja) 2013-06-20
EP2561368A2 (en) 2013-02-27
EP2561368B1 (en) 2017-08-02
US9766249B2 (en) 2017-09-19
KR101977875B1 (ko) 2019-05-13
EP2561368A4 (en) 2013-10-09
KR20130095183A (ko) 2013-08-27
JP6158078B2 (ja) 2017-07-05
CN102947706A (zh) 2013-02-27
WO2011133477A3 (en) 2012-05-10
AU2011242990A1 (en) 2012-11-01
JP2017106923A (ja) 2017-06-15
PL2561368T4 (pl) 2018-03-30

Similar Documents

Publication Publication Date Title
HK1258688A1 (zh) 预测药物敏感性、抗性和疾病进展的组合物和方法
Pinzani et al. Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase–polymerase chain reaction results and feasibility of molecular analysis by laser microdissection
Korde et al. Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer
Doane et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen
JP6864089B2 (ja) 進行性胃癌患者の手術後の予後または抗癌剤適合性予測システム
JP2015530072A (ja) ゲムシタビン療法による乳癌の治療方法
CN101861400A (zh) 患者的基于基因的算法型癌症预后和临床结果
JP2014514278A (ja) アントラサイクリン療法を用いて乳癌を処置する方法
US20150005264A1 (en) Predictive biomarker for hypoxia-activated prodrug therapy
US20120178093A1 (en) Methods of assessing a risk of cancer progression
CN113194934A (zh) 使用隐陡头菌素和生物标志物治疗实体肿瘤癌症的方法
CN104145030A (zh) 用于诊断肺癌侵袭性和遗传不稳定性的标记
CN108728533A (zh) 用于髓母细胞瘤分子分型的基因群以及snca基因作为4型髓母细胞瘤的生物标志物的用途
Ariyarathna et al. Chemokine gene expression influences metastasis and survival time of female dogs with mammary carcinoma
TWI598444B (zh) 用以評估乳癌罹患風險之方法及基因標記
JP2012085554A (ja) 乳がんのサブタイプの判別方法
US20250075275A1 (en) Gene/protein expression guided melanoma surgery
Rak-Makowska et al. MicroRNA signatures of invasiveness in PitNETs: a focus on miR-186-5p, miR-191-5p, miR-454-3p, and miR-590-5p
Saleh Isolation and Characterization of Human Breast Circulating Tumor Cells via Whole Blood Volume Apheresis
WO2022098619A1 (en) Compositions and methods for improving cancer therapy
Kang et al. Breast cancer in Brunei Darussalam− Differential community distribution and an analysis of common molecular tumour markers
Daidone et al. Human Solid Tumors: Assessing Their Impact in Clinical Oncology
Shao et al. PP67 Early alpha-fetoprotein response predicts treatment efficacy of anti-angiogenic therapy in combination with metronomic chemotherapy for advanced hepatocellular carcinoma